• Nurix Therapeutics Inc NRIX.OQ reported a quarterly adjusted loss of 67 cents​​ per share for the quarter ended February 28, higher than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 76 cents per share. Wall Street expected results to range from -96 cents to -50 cents per share.

• Revenue rose 11.3% to $18.45 million from a year ago; analysts expected $12.71 million.

• Nurix Therapeutics Inc's reported EPS for the quarter was a loss of 67 cents​.

• The company reported a quarterly loss of $56.35 million.

• Nurix Therapeutics Inc shares had fallen by 18.2% this quarter and lost 48.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Nurix Therapeutics Inc is $35.00

This summary was machine generated from LSEG data April 8 at 08:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)